Rafael Fonseca, MD
Enriched profileGetz Family Professor of Cancer, Professor of Medicine, and Chief Innovation Officer (also referred to as Director for Innovation and Transformational Relationships); consultant, Division of Hematology/Oncology · Mayo Clinic
Rafael Fonseca is Getz Family Professor of Cancer, Professor of Medicine, and Chief Innovation Officer (also referred to as Director for Innovation and Transformational Relationships); consultant, Division of Hematology/Oncology at Mayo Clinic. OpenAlex indexes 894 publications with 51,290 citations (h-index 121); ClinicalTrials.gov lists 3 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology profiles in the findmyKOL directory.
Data verified 28 Sept 2026
Overview
Updated 14 Oct 2026
Rafael Fonseca, MD, is Getz Family Professor of Cancer, Professor of Medicine, and Chief Innovation Officer (also referred to as Director for Innovation and Transformational Relationships) at Mayo Clinic, Arizona (Scottsdale/Phoenix). The public record shows 894 publications with 51,290 citations (h-index 121), centered on Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Chronic Lymphocytic Leukemia Research. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 25 companies, 2 NIH-funded awards (2004–2026).
- Most recent indexed publication: 2026 · Blood advances
- Top research focus: Multiple Myeloma Research and Treatments
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 25 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 38 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 356.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →goldwaterinstitute.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tribdem.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cotahealthcare.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
Sponsor: Mayo Clinic
- Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 14 Oct 2026
25 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Regeneron Pharmaceuticals, Inc.Program year202510 payments$27,861openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20254 payments$20,118openpaymentsdata.cms.gov ↗
- Janssen Global Services, LLCProgram year20258 payments$13,353openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
36.6%Thalidomide Analog30.2%Revlimid57%Pomalyst32%Lenalidomide11%Part D<11 patientsBCL-2 Inhibitor4.3%Venclexta100%Part D<11 patients+ 1 more class in this area
Dermatology
26.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor26.9%Acyclovir100%Part D≥39 patientsNervous system
15.4%Opioid Agonist8.3%Morphine Sulfate Er39%Oxycodone Hcl39%Fentanyl23%Part D<11 patientsBenzodiazepine4.9%Alprazolam52%Lorazepam48%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
2 NIH research awards on record, funded 2004–2026 per NIH RePORTER. The latest:
Congress activity
Updated 14 Oct 2026
119 congress contributions (2005–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Abstract 4537: Dynamics of B-cell repertoires following CAR-T and bispecific antibody therapy in multiple myeloma
AACR Annual Meeting
AACR2025Co-author - Ocular toxicity and tolerability of BCMA directed antibody drug conjugate (ADC) therapy in relapsed multiple myeloma (MM).
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Clinical Evaluation of Ex Vivo Expanded MUC1-Specific Peripheral Blood T Cells for Adoptive Immunotherapy in Relapsed/Refractory Multiple Myeloma.
Cancer research communications
Clinical Trial2026 - Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.
American journal of hematology
Article2026
Most-cited works
by citation count (OpenAlex)- 01Review of 1027 Patients With Newly Diagnosed Multiple Myeloma2,434 citations2003
- 02Initial genome sequencing and analysis of multiple myeloma1,440 citations2011
- 03
- 04
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/rafael-fonseca-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Other
rafaelfonseca.substack.com/p/myeloma-today
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →rafaelfonseca.substack.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Rafael-Fonseca-2172376069
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - LinkedIn
linkedin.com/in/rafa-fonseca-a69a763
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/MayoClinic/posts/dr-rafael-fonseca-a-mayo-clinic-hematologist-specializing-in-multiple-myeloma-an/1073731388122971
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Instagram
instagram.com/mayoclinic/p/CuhWaC2Mn2f
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗ - Other
oncologytoday.captivate.fm/episode/5493-oncologytodaypostash25-mm
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncologytoday.captivate.fm ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - Substack.com
Substack newsletter under his own byline ('Rafael Fonseca, M.D.')
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →substack.com ↗ - LinkedIn
LinkedIn profile 'Rafa Fonseca - Professor of Medicine at Mayo Clinic'
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- M.D.
Universidad Anáhuac México
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org ↗ - Residency
Internal Medicine, University of Miami, Florida
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org ↗ - Fellowship
Hematology and Oncology, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org ↗ - Board certified in Internal Medicine
Medical Oncology, and Hematology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Editorial & leadership roles
journal and society appointments- Editorial/reviewer roles for Blood
Leukemia, and other hematology-oncology journals
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →managingmyeloma.com ↗ - Member
American Society of Hematology (ASH)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗ - Member
American Society of Clinical Oncology (ASCO)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗ - Member
American Association for Cancer Research (AACR)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗ - Clinical Investigator
Damon Runyon Cancer Research Foundation
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗ - Former Director (Interim, Enterprise)
Mayo Clinic Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org ↗ - Former Chair
Department of Internal Medicine, Mayo Clinic Arizona
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →globenewswire.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
Secondary affiliations
appointments beyond the home institution- Visiting Fellow
Goldwater Institute (healthcare policy, free-market/patient-access advocacy)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →goldwaterinstitute.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →phoenixmag.com ↗
- Member
Mayo Clinic Board of Governors and Board of Trustees
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →phoenixmag.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →phoenixmag.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →azpbs.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cotahealthcare.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →audacy.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
S Rajkumar, MD
Mayo Clinic
Bradley Boeve, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic
Ayalew Tefferi, MD
Mayo Clinic
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens